專利保護智財權成果 北極星藥業ESG擴大新藥研發能量
Polaris is committed to the research and development of metabolic therapy cancer drugs to alleviate patients' discomfort and reduce treatment side effects. In 2022, the company will reach the milestone of blindness for mesothelial lung cancer, and many other cancers will enter Phase III clinical trials, and move toward obtaining national drug certificates. In addition, the company will also undertake the commissioned development and production of biopharmaceuticals (CDMO) services, and will increase its investment in research and development year by year, and will introduce an automated management system to monitor and control energy consumption in the future, In the future, we will introduce an automated management system to monitor energy consumption and hire more employees to expand our influence as a sustainable employer, so that we can walk side by side with the public on the road of new drug research and development in the long term.
研發投入逐年上升 專利保護智慧財產權成果
